A combination of three drugs — ivosidenib, venetoclax, and azacitidine — has achieved a composite complete remission rate of 90% in patients with IDH1-mutated acute myeloid leukemia, according to results from a Phase Ib/II study published in the Journal of Clinical Oncology and updated at ASH 2024. The triplet regimen also produced one-year survival rates of approximately 90%, a striking improvement over the roughly 50% one-year survival seen with the two-drug combination of ivosidenib and venetoclax alone. For families navigating both dementia caregiving and the fear of a cancer diagnosis in an aging loved one, these numbers represent a genuine shift in what is possible. This is not an isolated finding.
Across several recent clinical trials, leukemia treatments are now routinely crossing the 90% response threshold. The DAV regimen, which adds venetoclax to standard chemotherapy, achieved a 91% complete remission rate and 97% MRD negativity in newly diagnosed AML. In January 2026, the FDA granted Breakthrough Therapy Designation to a first-in-class antibody called IPN60340 for frontline AML. And in February 2026, the first all-oral fixed-duration combination for chronic lymphocytic leukemia won FDA approval. This article walks through what these breakthroughs mean, how they work, and what caregivers and patients should realistically expect.
Table of Contents
- What Does a 90% Response Rate in Leukemia Clinical Trials Actually Mean?
- How the Ivosidenib Triplet Works — and Where It Falls Short
- IPN60340 — A New Class of Leukemia Drug Earns FDA Breakthrough Status
- What the New CLL Approval Means for Older Adults and Their Caregivers
- When 90% Response Rates Do Not Tell the Whole Story
- The DAV and FLAG-IDA-Ven Regimens — Pushing Past 90%
- What Comes Next in Leukemia Treatment
- Conclusion
- Frequently Asked Questions
What Does a 90% Response Rate in Leukemia Clinical Trials Actually Mean?
A 90% response rate sounds like a near-cure, but it requires careful interpretation. In the ivosidenib triplet study, the 90% figure refers to composite complete remission — meaning that nine out of ten patients saw their leukemia reduced to undetectable or near-undetectable levels. Among those who could be evaluated for minimal residual disease, 63% achieved MRD-negative remissions, which is a deeper measure of how thoroughly the cancer was eliminated. Additionally, 64% of patients who received five or more treatment cycles saw their IDH1 mutation cleared entirely. Median event-free survival reached 36 months and median overall survival hit 42 months.
But response does not mean cure, and remission does not mean the disease is gone forever. Leukemia can relapse, especially in older adults who often cannot tolerate the most aggressive consolidation therapies. For dementia caregivers, this distinction matters enormously. A loved one who achieves remission may still face months of monitoring, blood draws, and clinic visits. The good news from this particular trial is that 91% of adverse events were grade 1 or 2 — meaning most side effects were mild to moderate — and the maximum tolerated dose was never reached. That tolerability profile is especially important for older patients who may already be managing cognitive decline or other chronic conditions.
How the Ivosidenib Triplet Works — and Where It Falls Short
The triplet combination targets a specific genetic mutation — IDH1 — found in roughly 6% to 10% of AML cases. Ivosidenib blocks the mutant IDH1 enzyme, venetoclax inhibits a protein called BCL-2 that helps leukemia cells survive, and azacitidine is a hypomethylating agent that disrupts the cancer cell’s ability to silence tumor-suppressing genes. Together, these three drugs attack the disease from different angles, which likely explains the jump from 83% remission with two drugs to 90% with all three. However, this regimen only works for patients whose leukemia carries the IDH1 mutation.
If a patient’s AML does not have that specific mutation, this particular triplet is not an option. Genetic testing at diagnosis is therefore essential, and not every hospital or oncology practice runs comprehensive molecular profiling automatically. Caregivers who are managing a loved one’s medical appointments — especially those already stretched thin by dementia care responsibilities — should specifically ask the oncology team whether full molecular testing has been completed. The difference between a targeted therapy that fits the genetic profile and one that does not can be the difference between a 90% remission rate and a far less favorable outcome.
IPN60340 — A New Class of Leukemia Drug Earns FDA Breakthrough Status
On January 13, 2026, the FDA granted Breakthrough Therapy Designation to IPN60340, also known as ICT01, developed by Ipsen. This is a first-in-class monoclonal antibody that targets BTN3A, an immune-regulatory molecule involved in how the body’s immune system recognizes and attacks cancer cells. In a single-arm trial of 38 patients, the combination of IPN60340 with venetoclax and azacitidine nearly doubled complete response rates compared to historical data for standard-of-care treatment across all molecular subtypes of AML. What makes IPN60340 noteworthy is that it is not limited to a single mutation subtype.
Unlike the ivosidenib triplet, which requires the IDH1 mutation, IPN60340 showed benefit across the molecular spectrum. Ipsen has stated that it plans to discuss Phase II/III trial design with the FDA in the first half of 2026. For patients and caregivers, this drug is not yet available outside of clinical trials, but the Breakthrough Therapy Designation means the FDA considers the early evidence strong enough to warrant an accelerated development path. It is worth monitoring, particularly for newly diagnosed AML patients who are not candidates for intensive chemotherapy.
What the New CLL Approval Means for Older Adults and Their Caregivers
On February 19, 2026, the FDA approved the combination of acalabrutinib (brand name Calquence) and venetoclax as the first all-oral, fixed-duration treatment for chronic lymphocytic leukemia. The approval was based on the AMPLIFY Phase III trial, which showed that 77% of patients remained progression-free at three years compared to those receiving chemoimmunotherapy. CLL is the most common leukemia in adults, and it disproportionately affects older populations — the same demographic most at risk for dementia and cognitive decline. The practical significance of an all-oral, fixed-duration regimen cannot be overstated for caregivers.
Previous CLL treatments often required intravenous infusions, indefinite treatment duration, or both. A fixed-duration oral regimen means fewer trips to infusion centers, a clearer treatment timeline, and less disruption to the daily routines that are so critical for people living with dementia. The tradeoff is that 77% progression-free survival at three years, while a real improvement over chemoimmunotherapy, still means roughly one in four patients will see their disease progress. Continuous therapy with a BTK inhibitor alone may offer longer disease control for some patients, so the choice between fixed-duration and continuous treatment should be an individualized conversation with the oncology team.
When 90% Response Rates Do Not Tell the Whole Story
Clinical trial populations are not the same as real-world patient populations. The patients enrolled in these studies were carefully selected based on specific criteria — organ function, performance status, and willingness to adhere to the trial protocol. Older adults with concurrent dementia are routinely excluded from clinical trials, which means the impressive response rates reported may not directly translate to someone managing both leukemia and significant cognitive impairment. There is also the matter of what happens after remission.
The ivosidenib triplet showed a median overall survival of 42 months — impressive, but not indefinite. Relapse remains a real possibility, and for patients with coexisting dementia, the decision about whether to pursue additional rounds of treatment after relapse involves deeply personal and ethical considerations. Caregivers should be aware that the oncology team may recommend ongoing monitoring even after successful treatment, and that maintaining treatment adherence can be particularly challenging in someone with progressive cognitive decline. Pill organizers, caregiver-administered medication schedules, and close coordination between the oncology and neurology teams become essential.
The DAV and FLAG-IDA-Ven Regimens — Pushing Past 90%
Two additional combination regimens have posted response rates that exceed even the ivosidenib triplet. The DAV regimen — which adds venetoclax to standard 7+3 induction chemotherapy — achieved a 91% complete remission rate and a remarkable 97% MRD negativity rate in newly diagnosed AML.
The FLAG-IDA-Ven regimen went further still, producing an overall response rate of 99%, a complete remission rate of 96%, and MRD negativity in 89% of patients. These are among the highest response rates ever reported in AML, though they come with the intensity of multi-drug chemotherapy, which limits their use in frail or elderly patients.
What Comes Next in Leukemia Treatment
The leukemia treatment landscape in 2026 is defined by precision. Molecular profiling at diagnosis now determines which of several highly effective regimens a patient should receive.
The FDA’s decision to grant Breakthrough Therapy Designation to IPN60340 signals that immunotherapy-based approaches may soon offer broad-spectrum alternatives to mutation-specific regimens. For caregivers and families, the most important takeaway is that leukemia diagnosed today carries a fundamentally different prognosis than it did even five years ago. Staying informed, asking about molecular testing, and discussing both the benefits and realistic limitations of new treatments with the care team are the most productive steps anyone can take.
Conclusion
Multiple leukemia drug combinations are now achieving response rates at or above 90% in clinical trials. The ivosidenib, venetoclax, and azacitidine triplet has produced a 90% composite complete remission rate and approximately 90% one-year survival in IDH1-mutant AML. The DAV and FLAG-IDA-Ven regimens have pushed those numbers even higher in broader AML populations. And the first all-oral fixed-duration CLL treatment — acalabrutinib plus venetoclax — was approved by the FDA in February 2026, offering a less burdensome option for older adults.
For families already managing the demands of dementia caregiving, a concurrent leukemia diagnosis is overwhelming. But the treatment options available today are markedly better than those of even the recent past. The key actions are ensuring complete molecular profiling at diagnosis, discussing both intensive and lower-intensity treatment options with the oncology team, and coordinating closely between all members of the care team. These advances do not erase the difficulty, but they meaningfully improve the odds.
Frequently Asked Questions
Does a 90% response rate mean 90% of leukemia patients are cured?
No. A response or remission rate measures how many patients see their cancer reduced to undetectable levels after treatment. Relapse can still occur. The ivosidenib triplet, for example, showed a median overall survival of 42 months, which is a major improvement but does not equate to a cure for all patients.
Are these new leukemia treatments available to someone who also has dementia?
That depends on the specific treatment and the patient’s overall health. Lower-intensity regimens like the ivosidenib triplet or the Calquence-venetoclax combination are generally better tolerated and more feasible for older adults. However, patients with dementia are typically excluded from clinical trials, so real-world outcomes may differ from trial results.
What is IDH1-mutant AML?
IDH1 is a gene that, when mutated, contributes to the development of acute myeloid leukemia in roughly 6% to 10% of cases. The ivosidenib triplet specifically targets this mutation, which is why molecular profiling at diagnosis is essential to determine eligibility.
What does MRD negativity mean?
MRD stands for minimal residual disease. MRD negativity means that no leukemia cells can be detected using highly sensitive laboratory tests, even after initial remission is achieved. Higher MRD negativity rates are generally associated with longer-lasting remissions.
Is the Calquence plus venetoclax combination only for CLL?
The FDA approval on February 19, 2026, is specifically for chronic lymphocytic leukemia and small lymphocytic lymphoma. It is not approved for AML or other leukemia subtypes. Different leukemia types require different treatment approaches.
